Progesterone Capsule
Product Images NDC 73190-065

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Progesterone (NDC 73190-065). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (064 01)

1 (064 01)
Packaging label for Progesterone Capsules 100 mg by AvKARE. The label indicates 100 capsules in the package, marked as prescription only. It includes warnings about peanut allergy and pharmacist instructions, storage conditions from 20°C to 25°C, and references to the USP standard. The label also displays the NDC 73190-064-01 and AvKARE contact information with website and manufacturing details.*
FDA Label Image

1 (065 01)

1 (065 01)
Progesterone Capsules 200 mg oral dosage form by AvKARE. The label displays the product name, strength, and capsule count of 100. It includes a warning about peanut allergy and instructions for pharmacists to dispense patient information. Storage instructions and manufacturing details in Paulsboro, NJ are also visible.*
FDA Label Image

Chem Structure (Progesterone Capsules 1)

Chem Structure (Progesterone Capsules 1)
Chemical structure of progesterone, showing its steroid backbone with characteristic four-ring structure and functional groups, consistent with the hormone's molecular configuration.*
FDA Label Image

Figure 1 (Progesterone Capsules 2)

Figure 1 (Progesterone Capsules 2)
A line graph showing the probability of hyperplasia over time in months (0 to 36 months) on medication. The graph compares four groups: Conjugated Estrogens Alone, Conjugated Estrogens Plus Micronized Progesterone (cyclical), Placebo Only, with patient counts noted at intervals (0, 12, 24, 36 months). The highest probability is seen in the Conjugated Estrogens Alone group, followed by the other groups with lower probabilities.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.